Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

REM-422

ARIA

Remix Therapeutics (merging with Passage Bio) · Phase 1/2 · Recruiting · Enrollment 125

NCT06118086

Catalyst Primary completion. 09.30.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Catalyst ENA 2026 late-breaking oral 5LBA (updated Phase 1). 11.19.2026. Company release 10.28.2026.

Catalyst Initial Phase 2 data (company guidance). H1 2027. Company statement: mid-2027.

ArmPopulationDoseEstimandComparatorEfficacy
REM-422 24 mg (RP2D), biomarker positiveR/M ACC, MYB biomarker positive at RP2D (n = 7)24 mgSingle armn/robjective response rate: 43%, cutoff 01.07.2026, Abstract 6009 states 42% (3 of 7)disease control rate: 100%, ASCO 2026
REM-422 12 mg or more, biomarker positivebiomarker-positive R/M ACC (n = 30)12 to 48 mgSingle armn/rany target-lesion reduction: 70%, cutoff 01.07.2026target-lesion shrinkage of 20% or more: 47%, cutoff 01.07.2026
REM-422 24 mg, safetyall patients at RP2D (n = 15)24 mgSingle armn/rn/r
REM-422 Phase 2 confirmatory cohortbiomarker-positive ACC (40 to 50 planned)24 mgSingle armn/rn/r